Rock Springs Capital Healthcare News

This is selected healthcare news for Rock Springs Capital, which is filed under Capital Firms. There are 658 news items for this page. Rock Springs Capital is occasionally combined with Vedanta Biosciences, Kindbody and Cerevel Therapeutics in news items. A press release filter page is also available for Rock Springs Capital.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source
11/28/2022 Franklin Resources Inc. Has $24.31 Million Stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)
... reduced their stakes in the business. Frazier Life Sciences Management L.P. acquired a new stake in Mirum Pharmaceuticals in the first quarter valued at $78,543,000. Rock Springs Capital Management LP increased its position in Mirum Pharmaceuticals by 8.3% during the first quarter. Rock Springs Capital Management LP now owns 1,666,208 ...
defenseworld.net
11/27/2022 Lazard Asset Management LLC Acquires Shares of 2,442 Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)
... reduced their stakes in the stock. Frazier Life Sciences Management L.P. acquired a new position in Mirum Pharmaceuticals in the 1st quarter valued at $78,543,000. Rock Springs Capital Management LP raised its holdings in Mirum Pharmaceuticals by 8.3% in the 1st quarter. Rock Springs Capital Management LP now owns 1,666,208 ...
etfdailynews.com
11/24/2022 Cibc World Market Inc. Sells 20,654 Shares of ESSA Pharma Inc. (NASDAQ:EPIX)
... during the last quarter. Jane Street Group LLC bought a new stake in shares of ESSA Pharma during the 1st quarter valued at about $154,000. Rock Springs Capital Management LP boosted its position in shares of ESSA Pharma by 2.7% during the 1st quarter. Rock Springs Capital Management LP now ...
etfdailynews.com
11/19/2022 Walleye Capital LLC Makes New $264,000 Investment in Blueprint Medicines Co. (NASDAQ:BPMC)
... during the period. Aigen Investment Management LP acquired a new position in shares of Blueprint Medicines in the first quarter valued at approximately $570,000. Finally, Rock Springs Capital Management LP increased its stake in shares of Blueprint Medicines by 10.2% in the first quarter. Rock Springs Capital Management LP now ...
etfdailynews.com
11/16/2022 CinCor Pharma, Inc. (NASDAQ:CINC) Sees Significant Increase in Short Interest
... during the 1st quarter worth $34,742,000. RTW Investments LP purchased a new stake in shares of CinCor Pharma during the first quarter worth about $24,375,000. Rock Springs Capital Management LP acquired a new position in shares of CinCor Pharma during the first quarter valued at about $18,087,000. Perceptive Advisors LLC ...
etfdailynews.com
11/16/2022 Walleye Capital LLC Makes New $484,000 Investment in Inozyme Pharma, Inc. (NASDAQ:INZY) - Ticker Report
... the company's stock, valued at approximately $484,000. A number of other large investors have also added to or reduced their stakes in the company. Rock Springs Capital Management LP boosted its stake in shares of Inozyme Pharma by 37.4% during the 1st quarter. Rock Springs Capital Management LP now ...
Ticker Report
11/16/2022 Walleye Capital LLC Has $552,000 Stock Holdings in CinCor Pharma, Inc. (NASDAQ:CINC)
... during the 1st quarter worth approximately $34,742,000. RTW Investments LP acquired a new stake in CinCor Pharma in the first quarter valued at approximately $24,375,000. Rock Springs Capital Management LP acquired a new stake in CinCor Pharma in the first quarter valued at approximately $18,087,000. Omega Fund Management LLC acquired ...
baseballnewssource.com
11/15/2022 SG Americas Securities LLC Purchases 39,602 Shares of Invitae Co. (NYSE:NVTA)
... Management LLC now owns 28,668,950 shares of the medical research company's stock worth $105,215,000 after purchasing an additional 986,724 shares in the last quarter. Rock Springs Capital Management LP raised its stake in shares of Invitae by 18.7% in the first quarter. Rock Springs Capital Management LP now owns ...
etfdailynews.com
11/14/2022 TownSquare Capital LLC Trims Stake in Invitae Co. (NYSE:NVTA) - Ticker Report
... Inc. now owns 19,515,586 shares of the medical research company's stock valued at $155,540,000 after buying an additional 69,702 shares during the last quarter. Rock Springs Capital Management LP lifted its stake in shares of Invitae by 18.7% during the first quarter. Rock Springs Capital Management LP now owns ...
Ticker Report
11/14/2022 Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Shares Sold by 1492 Capital Management LLC - Transcript Daily
... Pharmaceuticals were worth $944,000 as of its most recent SEC filing. Other hedge funds also recently added to or reduced their stakes in the company. Rock Springs Capital Management LP lifted its holdings in Paratek Pharmaceuticals by 1.7% during the 1st quarter. Rock Springs Capital Management LP now owns 1,726,637 ...
transcriptdaily.com
11/12/2022 Invitae Co. (NYSE:NVTA) Shares Purchased by State of Michigan Retirement System - Ticker Report
... Vanguard Group Inc. now owns 19,515,586 shares of the medical research company's stock worth $155,540,000 after buying an additional 69,702 shares during the period. Rock Springs Capital Management LP increased its stake in Invitae by 18.7% during the 1st quarter. Rock Springs Capital Management LP now owns 3,323,821 shares ...
Ticker Report
11/10/2022 Zenas BioPharma raises $118m Series B round to advance pipeline
... a $300-million platform backed by Menlo Park-based healthcare investment firm Patient Square Capital, it announced in a recent statement. New investors Longitude Capital, Rock Springs Capital, Perceptive Advisors, Agent Capital, Pivotal bioVenture Partners, and Superstring Capital participated in the deal. Vivo Capital, which has backed WuXi AppTec and ...
dealstreetasia.com
11/9/2022 Zenas BioPharma Secures $118 Million to Advance Its Broad Pipeline of Autoimmune Disease Therapeutics
... of Series B preferred shares. In addition to Enavate Sciences, which led the Series B equity financing, new Zenas shareholders include Longitude Capital, Vivo Capital, Rock Springs Capital, Perceptive Advisors, Agent Capital, Pivotal bioVenture Partners and Superstring Capital. Existing investors Fairmount, Wellington Management, Tellus BioVentures, Quan Venture Fund, and Xencor ...
indonesiatribune.com
11/9/2022 Zenas BioPharma Secures $118 Million to Advance Its Broad Pipeline of Autoimmune Disease Therapeutics
... of Series B preferred shares. In addition to Enavate Sciences, which led the Series B equity financing, new Zenas shareholders include Longitude Capital, Vivo Capital, Rock Springs Capital, Perceptive Advisors, Agent Capital, Pivotal bioVenture Partners and Superstring Capital. Existing investors Fairmount, Wellington Management, Tellus BioVentures, Quan Venture Fund, and Xencor ...
Yahoo News
11/9/2022 Zenas BioPharma Secures $118 Million to Advance Its Broad Pipeline of Autoimmune Disease Therapeutics
... of Series B preferred shares. In addition to Enavate Sciences, which led the Series B equity financing, new Zenas shareholders include Longitude Capital, Vivo Capital, Rock Springs Capital, Perceptive Advisors, Agent Capital, Pivotal bioVenture Partners and Superstring Capital. Existing investors Fairmount, Wellington Management, Tellus BioVentures, Quan Venture Fund, and Xencor ...
philippinesnewsgazette.com
11/9/2022 Zenas BioPharma Secures $118 Million to Advance Its Broad Pipeline of Autoimmune Disease Therapeutics
... of Series B preferred shares. In addition to Enavate Sciences, which led the Series B equity financing, new Zenas shareholders include Longitude Capital, Vivo Capital, Rock Springs Capital, Perceptive Advisors, Agent Capital, Pivotal bioVenture Partners and Superstring Capital. Existing investors Fairmount, Wellington Management, Tellus BioVentures, Quan Venture Fund, and Xencor ...
cambodiatribune.com
11/9/2022 Zenas BioPharma Secures $118 Million to Advance Its Broad Pipeline of Autoimmune Disease Therapeutics
... of Series B preferred shares. In addition to Enavate Sciences, which led the Series B equity financing, new Zenas shareholders include Longitude Capital, Vivo Capital, Rock Springs Capital, Perceptive Advisors, Agent Capital, Pivotal bioVenture Partners and Superstring Capital. Existing investors Fairmount, Wellington Management, Tellus BioVentures, Quan Venture Fund, and Xencor ...
thailandnewsgazette.com
11/9/2022 Zenas BioPharma Secures $118 Million to Advance Its Broad Pipeline of Autoimmune Disease Therapeutics
... of Series B preferred shares. In addition to Enavate Sciences, which led the Series B equity financing, new Zenas shareholders include Longitude Capital, Vivo Capital, Rock Springs Capital, Perceptive Advisors, Agent Capital, Pivotal bioVenture Partners and Superstring Capital. Existing investors Fairmount, Wellington Management, Tellus BioVentures, Quan Venture Fund, and Xencor ...
singaporenewstribe.com
11/7/2022 Employees Retirement System of Texas Takes Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
... quarter. Candriam S.C.A. now owns 863,140 shares of the biopharmaceutical company's stock worth $26,255,000 after buying an additional 258,886 shares in the last quarter. Rock Springs Capital Management LP raised its holdings in shares of Xenon Pharmaceuticals by 9.2% in the 1st quarter. Rock Springs Capital Management LP now ...
Daily Political
11/7/2022 Employees Retirement System of Texas Takes Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - The Cerbat Gem
... quarter. Candriam S.C.A. now owns 863,140 shares of the biopharmaceutical company's stock worth $26,255,000 after buying an additional 258,886 shares in the last quarter. Rock Springs Capital Management LP raised its holdings in shares of Xenon Pharmaceuticals by 9.2% in the 1st quarter. Rock Springs Capital Management LP now ...
thecerbatgem.com
11/7/2022 Zenas BioPharma Secures $118 Million to Advance Its Broad
... of Series B preferred shares. In addition to Enavate Sciences, which led the Series B equity financing, new Zenas shareholders include Longitude Capital, Vivo Capital, Rock Springs Capital, Perceptive Advisors, Agent Capital, Pivotal bioVenture Partners and Superstring Capital. Existing investors Fairmount, Wellington Management, Tellus BioVentures, Quan Venture Fund, and Xencor ...
Globe Newswire
11/5/2022 Victory Capital Management Inc. Grows Stock Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)
... worth approximately $16,405,000. First Light Asset Management LLC purchased a new position in shares of Mirum Pharmaceuticals during the 1st quarter worth approximately $4,735,000. Finally, Rock Springs Capital Management LP boosted its stake in shares of Mirum Pharmaceuticals by 8.3% in the first quarter. Rock Springs Capital Management LP now ...
etfdailynews.com
11/4/2022 US Bancorp DE Lowers Holdings in Evolent Health, Inc. (NYSE:EVH)
... Co. L P now owns 2,526,959 shares of the technology company's stock worth $81,621,000 after purchasing an additional 544,667 shares during the last quarter. Rock Springs Capital Management LP raised its position in Evolent Health by 16.8% in the 1st quarter. Rock Springs Capital Management LP now owns 2,380,000 ...
etfdailynews.com
11/4/2022 Insider Selling: Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Chairman Sells $20,820.00 in Stock
... post -0.92 EPS for the current year. A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Rock Springs Capital Management LP boosted its stake in shares of Paratek Pharmaceuticals by 1.7% during the first quarter. Rock Springs Capital Management LP now ...
Daily Political
11/4/2022 Evolent Health, Inc. (NYSE:EVH) Director Frank J. Williams Sells 110,000 Shares - Ticker Report
... P now owns 2,526,959 shares of the technology company's stock valued at $81,621,000 after buying an additional 544,667 shares in the last quarter. Finally, Rock Springs Capital Management LP grew its stake in Evolent Health by 16.8% during the 1st quarter. Rock Springs Capital Management LP now owns 2,380,000 ...
Ticker Report